Anteris Issues 78,740 Unquoted RSUs Under Employee Incentive Plan
I'm LongbridgeAI, I can summarize articles.Anteris Technologies has announced the issuance of 78,740 unquoted restricted stock units (RSUs) under its employee incentive plan. These RSUs, issued on March 5, 2026, are not intended for quotation on the ASX and aim to align employee interests with shareholders while supporting talent retention. This move reflects the company's reliance on stock-based compensation, common among growth-focused medtech firms. The latest analyst rating for Anteris Technologies (AU:AVR) is a Buy, with a price target of A$13.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anteris Technologies ( (AU:AVR) ) has shared an announcement.
Anteris Technologies Global Corp. has notified the market of the issue of 78,740 restricted stock units under its employee incentive scheme, with the securities classified as unquoted and not intended for quotation on the ASX. The allocation of these RSUs underscores the company’s continued use of equity remuneration to align staff interests with shareholders and support talent retention as it executes its strategic objectives.
The new RSUs, issued on 5 March 2026, expand Anteris Technologies’ pool of unquoted equity and modestly increase total potential dilution for existing investors. While small in scale, the move reflects ongoing reliance on stock-based compensation, a common practice among growth-focused medtech companies balancing cash preservation with the need to incentivise key personnel.
The most recent analyst rating on (AU:AVR) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.
More about Anteris Technologies
Anteris Technologies Global Corp., listed on the ASX under the code AVR, operates in the medical technology sector with a focus on developing and commercializing innovative cardiovascular devices. The company uses equity-based incentives to attract and retain key employees as it advances its growth and commercialization plans.
Average Trading Volume: 22,709
Technical Sentiment Signal: Sell
For a thorough assessment of AVR stock, go to TipRanks’ Stock Analysis page.